Efficacy of MT-401 in Patients With AML Following Stem Cell Transplant
Trial details
- Registry ID
- NCT04511130
- Drugs studied
- MT-401
TrialRedline tracks 1 clinical trial sponsored by Marker Therapeutics, Inc.: 1 Phase 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Efficacy of MT-401 in Patients With AML Following Stem Cell TransplantNCT04511130 | MT-401 | Terminated | 2024-03-01Actual |
Names as written in the registry records.